Jeffrey W. Albers
Director at Kymera Therapeutics, Inc. (KYMR); Director at Spyre Therapeutics, Inc. (SYRE)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Aug 10SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 5,000 | $104.47 | $522K | -18.0% |
| Aug 10SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 8,00019,360 held (−29%) | $104.38 | $835K | -17.9% |
| Aug 10SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 10,0009,360 held (−52%) | $104.68 | $1.0M | -18.1% |
| Dec 8SEC | KYMRKymera Therapeutics, Inc. | Sell Plan | 2,7482,252 held (−55%) | $89.32 | $245K | +25.8% |
| Dec 8SEC | KYMRKymera Therapeutics, Inc. | Sell Plan | 2,252 | $90.30 | $203K | +24.5% |
| Oct 14SEC | KYMRKymera Therapeutics, Inc. | Sell Plan | 5,000 | $59.19 | $296K | +89.9% |
- Sell
Director Jeffrey W. Albers sold $522K of SYRE at $104.47 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Jeffrey W. Albers sold $835K of SYRE at $104.38 — cuts the stake by 29%; pre-scheduled 10b5-1 plan sale.
- Sell
Director Jeffrey W. Albers sold $1.0M of SYRE at $104.68 — cuts the stake by 52%; pre-scheduled 10b5-1 plan sale.
- Sell
Director Jeffrey W. Albers sold $245K of KYMR at $89.32 — cuts the stake by 55%; pre-scheduled 10b5-1 plan sale.
- Sell
Director Jeffrey W. Albers sold $203K of KYMR at $90.30 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Jeffrey W. Albers sold $296K of KYMR at $59.19 — pre-scheduled 10b5-1 plan sale.